PMID- 16899204
OWN - NLM
STAT- MEDLINE
DCOM- 20061222
LR  - 20191110
IS  - 1529-7322 (Print)
IS  - 1529-7322 (Linking)
VI  - 6
IP  - 5
DP  - 2006 Sep
TI  - Mite immunotherapy.
PG  - 413-9
AB  - Dermatophagoides pteronyssinus and D. farinae are the most common house dust 
      mites and are among the most common sources of indoor allergens worldwide. These 
      species are very common in humid regions, where most allergic individuals are 
      sensitized to house dust mites. Specific immunotherapy with mite extracts has 
      demonstrated clinical benefits in several double-blind, placebo-controlled trials 
      that are included in recent reviews of subcutaneous immunotherapy, including 
      pediatric and adult patients with rhinoconjunctivitis and or asthma. Most 
      successful studies of mite immunotherapy have used native allergen extracts 
      adsorbed onto aluminum hydroxide, or chemically modified mite-allergen extracts. 
      Several studies have also shown efficacy using sublingual immunotherapy in 
      pediatric and adult patients with asthma and/or rhinitis. Additionally, the 
      efficacy of subcutaneous immunotherapy has been demonstrated in patients with 
      atopic dermatitis, although more double-blind, placebo-controlled studies are 
      needed. Based on several studies, it cannot be concluded that mite immunotherapy 
      is more dangerous or safer than immunotherapy with grasses, epithelia, or animal 
      epithelia. Because the delivery of high doses of allergen carries with it the 
      risk for immunoglobulin E (IgE)-mediated events, several methods have been 
      developed to reduce specific IgE binding to mite-allergen extracts. An important 
      challenge for future mite immunotherapy modalities is the delivery of relatively 
      high doses without a significant risk for severe reactions.
FAU - Fernandez-Caldas, Enrique
AU  - Fernandez-Caldas E
AD  - Laboratorios LETI, SL, Calle del Sol,5, 28760 Tres Cantos, Madrid, Spain. 
      efernandez@leti.com
FAU - Iraola, Victor
AU  - Iraola V
FAU - Boquete, Manuel
AU  - Boquete M
FAU - Nieto, Antonio
AU  - Nieto A
FAU - Casanovas, Miguel
AU  - Casanovas M
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Curr Allergy Asthma Rep
JT  - Current allergy and asthma reports
JID - 101096440
RN  - 0 (Allergens)
RN  - 0 (Antigens, Dermatophagoides)
SB  - IM
MH  - Allergens/therapeutic use
MH  - Animals
MH  - Antigens, Dermatophagoides/adverse effects/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Cross Reactions
MH  - *Desensitization, Immunologic/adverse effects
MH  - Humans
MH  - Pyroglyphidae/*immunology
MH  - Respiratory Hypersensitivity/therapy
RF  - 77
EDAT- 2006/08/11 09:00
MHDA- 2006/12/23 09:00
CRDT- 2006/08/11 09:00
PHST- 2006/08/11 09:00 [pubmed]
PHST- 2006/12/23 09:00 [medline]
PHST- 2006/08/11 09:00 [entrez]
AID - 10.1007/s11882-996-0015-6 [doi]
PST - ppublish
SO  - Curr Allergy Asthma Rep. 2006 Sep;6(5):413-9. doi: 10.1007/s11882-996-0015-6.